Bosnalijek Enterofuril capsules 100mg �30

pharmachologic effect

Enterofuril is a broad-spectrum antimicrobial agent, a derivative of 5-nitrofuran.

It is assumed that the antimicrobial activity of nifuroxazide is caused by the presence in its composition of the NO2 group, which inhibits the activity of dehydrogenase and disrupts protein synthesis in pathogenic bacteria.

It is active against gram-positive microorganisms (Streptococcus aureus, Staphylococcus pyogenes, Clostridium), gram-negative enterobacteria - E. coli, Salmonella spp., Shigella spp., Klebsiella spp., Enterobacter spp., Vibrio cholobacterialebacteri, enterobacter spp., Vibrio cholobacteriarae, Campitars ...

Nifuroxazide has no effect on the saprophytic flora, does not disturb the balance of normal intestinal flora.

In case of acute bacterial diarrhea, it restores intestinal eubiosis.

When infected with enterotropic viruses, it prevents the development of bacterial superinfection.

Pharmacokinetics

After oral administration, nifuroxazide is practically not absorbed from the digestive tract and has its antibacterial effect exclusively in the intestinal lumen.

Completely excreted through the digestive tract.

The rate of elimination depends both on the dose of the drug and on the motility of the intestinal tract.

Indications

Diarrhea of ​​bacterial origin.

Contraindications

hypersensitivity to nitrofuran derivatives or other components of the drug

fructose intolerance, glucose-galactose malabsorption syndrome or sucrase and isomaltase deficiency.

children under 3 years old.

Application during pregnancy and lactation

The use of the drug Enterofuril during pregnancy is possible only in cases where the expected benefit of therapy to the mother outweighs the potential risk to the fetus.

Enterofuril is not absorbed from the gastrointestinal tract and does not enter the systemic circulation, however, the use of the drug during lactation is possible only for strict indications, and the issue of stopping breastfeeding should be resolved.

special instructions

When treating diarrhea concurrently with nifuroxazide therapy, rehydration therapy (oral or intravenous) should be carried out in accordance with the patient's condition and the intensity of the diarrhea.

The use of alcohol during therapy with nifuroxazide is prohibited.

Before prescribing a suspension for infants, it is necessary to exclude their congenital deficiency of enzymes that break down sucrose.

Influence on the ability to drive vehicles and work with mechanisms.

The drug does not affect psychomotor activity and the ability to drive vehicles and work with mechanisms.

Structure

1 capsule contains:

active substance: nifuroxazide 100 mg,

excipients: sucrose - 36 mg

corn starch - 41.12 mg

MCC - 5.1 mg

magnesium stearate - 3.78 mg

shell: gelatin

titanium dioxide

dye iron oxide yellow.

Method of administration and dosage

Inside.

Nifuroxazide therapy should not be continued for more than 7 days.

For adults and children over 7 years of age, the drug is prescribed 1 capsule (200 mg) 4 times a day, the daily dose is 800 mg.

For children 3–7 years old, the drug is prescribed 1 capsule (200 mg) 3 times a day, the daily dose is 600 mg.

Side effects

Allergic reactions (rash, urticaria, Quincke's edema, anaphylactic shock), nausea, vomiting.

Drug interactions

Not described.

Overdose

The drug is not absorbed from the gastrointestinal tract and does not enter the systemic circulation.

Overdose symptoms are not known.

If the dose is exceeded, gastric lavage and symptomatic treatment are recommended.

Storage conditions

At temperatures between 15 and 30 ° C.

Shelf life

3 years.

Active substance

Nifuroxazide

Name ENG

ENTEROFURYL

Clinical and pharmacological group

Intestinal antiseptic.

Antidiarrheal drug

ATX code

Nifuroxazide

Dosage

100mg

Structure

1 capsule contains: active substance: nifuroxazide 100 mg, auxiliary substances: sucrose - 36 mg

corn starch - 41.12 mg

MCC - 5.1 mg

magnesium stearate - 3.78 mg shell: gelatin

titanium dioxide

dye iron oxide yellow.

Indications

Diarrhea of ​​bacterial origin.

INN / Active ingredient

nifuroxazide

Storage conditions and periods

At a temperature not higher than 30 degrees.

Expiration date: 5 years

Contraindications

Hypersensitivity to nitrofuran derivatives or other components of the drug

fructose intolerance, glucose-galactose malabsorption syndrome or sucrase and isomaltase deficiency

children under 3 years old.

Specifications

Category

Diarrhea

Scope of the drug

Gastrointestinal tract

Release form

Capsules

Manufacturer country

Bosnia and Herzegovina

Package quantity, pcs

thirty

Scope of application

Gastroenterology

Minimum age from

3 years old

Vacation conditions

Without recipe

Brand name

Bosnalijek

The amount of the dosage form in the primary package

10 pieces.

Primary packaging type

Blister

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Antimicrobial agent - nitrofuran

Anatomical and therapeutic characteristics

A07AX03 Nifuroxazide

Dosage form

Capsules

Packaging

Cardboard box

The target audience

Children

Dosage (volume) of the substance in the preparation

1 capsule contains: Nifuroxazide 100 mg < br> < br>

Expiration date in days

1095

Package weight, g

thirty

Mode of application

:

Inside.

Therapy with nifuroxazide should not last more than 7 days. < br> For adults and children over 7 years old, the drug is prescribed 1 capsule (200 mg) 4 times a day, the daily dose is 800 mg. < br> For children 3-7 years old, the drug is prescribed 1 capsule (200 mg) 3 times a day, the daily dose is 600 mg.

Information on technical characteristics, delivery set, country of manufacture